GSK’s HIV treatment, ‘Triumeq’ lands in approximately s30 major hospitals

GSK(CEO Yoo-seok Hong) invigorates ‘Triumeq’ prescriptions.

According to GSK, ‘Triumeq(dolutegravir 50mg, abacavir 600mg, lamivudine 300mg),’ a complex HIV treatment which contains dolutegravir for the first time, has become a drug which can be prescribed for a number of HIV patients as going through therapeutics committees of approximately 30 hospitals including Seoul National University Hosp...